Ergomed PLC (LON:ERGO) said its PrimeVigilance business, a global provider of pharmacovigilance and medical information services, established a new legal entity and regional office in Japan and is fully operational from today.
The new Tokyo-based subsidiary company, trading as PrimeVigilance Japan KK, offers a range of pharmacovigilance services, including a dedicated Japanese safety database and provides full medical information services in Japanese.
The expansion gives PrimeVigilance clients the opportunity to extend their product coverage into the Japanese pharmaceutical market, the fourth-largest in the world after the US, the EU and China, the pharmaceutical services company said.
“Ergomed has provided a breadth of services and expertise in Asia both as a CRO [Contract Research Organisation] and as a pharmacovigilance specialist through its outsourcing model for many years,” said executive chairman Dr Miroslav Reljanović.
“With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region.
“Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist.”